LiveSpo® NAVAX represents a groundbreaking advance in non-antibiotic respiratory care through the development of a spore-based probiotic nasal spray. Created by Vietnamese scientists, NAVAX utilizes Bacillus spore-forming probiotics that can penetrate deep into nasal passages and the middle ear, where they work by modulating inflammation and enhancing mucosal immunity. Unlike traditional therapies that rely heavily on antibiotics, NAVAX offers a novel mechanism of action—competing with pathogenic bacteria and boosting local immune responses. The product has now been validated by three international studies, with the most recent published in Scientific Reports – Nature, a testament to its scientific credibility and global potential.

The recent clinical study involving 126 patients, both children and adults, demonstrated that NAVAX delivers rapid and significant symptom relief. Among children suffering from rhinosinusitis and otitis media, 97% had no nasal discharge and 100% had no ear discharge after just 7 days of use, without any recorded side effects—even in immunocompromised children. In adults with sinusitis, NAVAX significantly reduced nasal congestion, facial pain, and purulent discharge within three days. The results also showed a dramatic decrease in pathogens such as Streptococcus pneumoniae and Haemophilus influenzae, confirming its effectiveness as a first-line, non-antibiotic therapy in primary care.

LiveSpo® NAVAX is not only a technological innovation but also a meaningful step toward reshaping how we approach common respiratory infections. By offering a safe, effective, and sustainable alternative to antibiotics, it reduces the risk of antimicrobial resistance and supports global public health goals. Its publication in high-impact scientific journals and strong clinical outcomes underline Vietnam’s growing prominence in biomedical research. With ongoing research and expanding global interest, NAVAX is positioned to become a cornerstone in the future of respiratory infection treatment—especially for vulnerable populations like children.

MedTech Spectrum's Summary

Innovative Non-Antibiotic Treatment : LiveSpo® NAVAX is the first nasal-spray probiotic using spore-forming Bacillus strains to treat respiratory infections by enhancing mucosal immunity and reducing inflammation—offering a novel alternative to antibiotics.

Clinically Proven Efficacy : In a large clinical study, NAVAX showed rapid symptom relief and over 90% recovery rates in children and adults with rhinosinusitis and otitis media, with no recorded side effects, even in immunocompromised patients.

Global Impact and Recognition : Published in Scientific Reports – Nature, NAVAX underscores Vietnam's scientific advancement and sets a new benchmark for safe, sustainable respiratory care worldwide, addressing antibiotic overuse in vulnerable populations.